Clinical trial
Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer
NCT00004890 · BioMedicines, Industry · Completed
Key facts
| NCT number | NCT00004890 |
|---|---|
| Title | Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer |
| Official title | Phase IB Open-Label Rising-Dose Study of Biomed 101 in Patients Treated With Interleukin-2 for Malignancy |
| Lead sponsor | BioMedicines, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Drug Extravasation, Kidney Cancer |
| Intervention type | Biological, Drug |
| Interventions | aldesleukin, Biomed 101 |
| Start date | Dec 1, 2000 |
| Primary completion | Dec 1, 2002 |
| Completion | Dec 1, 2002 |
| First posted | Dec 16, 2003 |
| Last update posted | Mar 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: